|
Jul 30
|
Merck Shares Fall After Drugmaker Cuts 2024 Outlook
|
|
Jul 30
|
Merck Falls as HPV Vaccine Miss Overshadows Profit, Sales Beat
|
|
Jul 30
|
Q2 earnings: Has Pfizer bucked declining COVID business?
|
|
Jul 30
|
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
|
|
Jul 30
|
Concern over Merck's Gardasil sales in China sink shares
|
|
Jul 30
|
Merck Announces Second-Quarter 2024 Financial Results
|
|
Jul 30
|
Pfizer, JetBlue, PayPal rise premarket; Merck, CrowdStrike, Diageo fall
|
|
Jul 28
|
Merck & Co., Inc.'s (NYSE:MRK) Dismal Stock Performance Reflects Weak Fundamentals
|
|
Jul 26
|
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
|
|
Jul 24
|
MSD reports positive topline data from Phase IIb/III RSV trial in infants
|
|
Jul 23
|
Merck Competes With Sanofi/AstraZeneca As Its RSV Treatment Drug Meets Primary Goal In Late-Stage Study In Infants
|
|
Jul 23
|
Merck Announces Fourth-Quarter 2024 Dividend
|
|
Jul 23
|
Should You Buy, Sell or Hold Merck (MRK) Ahead of Q2 Earnings?
|
|
Jul 23
|
Billionaires Are Loading Up on This Surging Dow Stock. Should You?
|
|
Jul 23
|
Merck claims late-stage study success for RSV antibody
|
|
Jul 23
|
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
|
|
Jul 23
|
Nanotechnology in medicine: Who are the leading public companies?
|
|
Jun 30
|
Questor: This ‘wonder drug’ firm is being backed by top fund managers
|
|
Jun 29
|
How Do These 3 Healthcare Dividend Stocks Deliver Reliable Income And Growth?
|
|
Jun 28
|
How Medicare drug price negotiations could hit pharma stocks
|